Daily Stock Market News

Reviewing Corvus Pharmaceuticals (NASDAQ:CRVS) and Pharmaxis (OTCMKTS:PXSLY)



Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) and Pharmaxis (OTCMKTS:PXSLYGet Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Corvus Pharmaceuticals and Pharmaxis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals 0 1 3 0 2.75
Pharmaxis 0 0 0 0 N/A

Corvus Pharmaceuticals currently has a consensus price target of $6.38, indicating a potential upside of 358.63%. Given Corvus Pharmaceuticals’ higher possible upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Pharmaxis.

Risk and Volatility

Corvus Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Pharmaxis has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Profitability

This table compares Corvus Pharmaceuticals and Pharmaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corvus Pharmaceuticals N/A -44.00% -38.66%
Pharmaxis N/A N/A N/A

Earnings and Valuation

This table compares Corvus Pharmaceuticals and Pharmaxis’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corvus Pharmaceuticals N/A N/A -$43.24 million ($1.06) -1.31
Pharmaxis $8.75 million 3.03 -$9.36 million N/A N/A

Pharmaxis has higher revenue and earnings than Corvus Pharmaceuticals.

Insider and Institutional Ownership

77.9% of Corvus Pharmaceuticals shares are held by institutional investors. 45.1% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Pharmaxis beats Corvus Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Corvus Pharmaceuticals (Get Rating)

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

About Pharmaxis (Get Rating)

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company’s product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.



Receive News & Ratings for Corvus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.



Read More: Reviewing Corvus Pharmaceuticals (NASDAQ:CRVS) and Pharmaxis (OTCMKTS:PXSLY)

You might also like